SCHEMBL1503902

SCHEMBL1503902

CN(C)C(=O)[C@H]1CCCC(N(NC(=O)c2cnc3cc(Cl)ccc3c2)C(=O)O)C1

nearest known ligand 0.48

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
F10 P00742 6/20 0.48
ACKR3 P25106 1/20 0.39
HPGDS O60760 10/20 0.39
MAOB P27338 2/20 0.36
ATF4 P18848 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4270734 0.88 F10 (0.45) F10ACKR3HPGDSMAOBATF4
SCHEMBL1503895 0.87 F10 (0.48) F10
SCHEMBL1503944 0.84 F10 (0.48) F10HPGDS
SCHEMBL1504044 0.83 F10 (0.48) F10ATF4
SCHEMBL1504174 0.80 F10 (0.42) F10
SCHEMBL1503898 0.77 F10 (0.67) F10
SCHEMBL1504340 0.75 F10 (0.45) F10ATF4
SCHEMBL2940967 0.75 F10 (0.56) F10ACKR3HPGDS
SCHEMBL4261592 0.74 F10 (0.43) F10
SCHEMBL1503995 0.74 L3MBTL1 (0.44) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1405852-B9 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-03-27 EP disclosed
EP-1405852-B1 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2012-08-01 EP disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
US-20090270446-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-10-29 US disclosed
US-7365205-B2 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-04-29 US disclosed
US-7342014-B2 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-11 US disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 US disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270446-A1 DIAMINE DERIVATIVES F2, TFPI, F3 F10 4/4885ACKR3 829/4885HPGDS 468/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R F10 196/4885ACKR3 1456/4885HPGDS 386/4885
US-20080015215-A1 DIAMINE DERIVATIVES C9, C1S, C1R F10 196/4885ACKR3 1456/4885HPGDS 386/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R F10 196/4885ACKR3 1456/4885HPGDS 386/4885
US-20110077266-A1 Diamine Derivatives F2, TFPI, F3 F10 4/4885ACKR3 829/4885HPGDS 468/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R F10 138/4885ACKR3 1152/4885HPGDS 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.